Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

Annals of Neurology

Volumn 46, Issue 4, 1999, Pages 598-605

  Langston, J W ^a   Forno, L S ^b   Tetrud, J ^a   Reeves, A G ^c   Kaplan, J A ^c,d   Karluk, D ^c  

^a PARKINSON S INSTITUTE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d Office of the Chief Medical Examiner   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROMOCRIPTINE; CARBIDOPA; LEVODOPA;

ADULT; ARTICLE; CASE REPORT; DRUG DEPENDENCE; ELECTRON MICROSCOPY; GLIOSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SURVIVAL TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADULT; CELL DEATH; HUMANS; MALE; NERVE DEGENERATION; SUBSTANTIA NIGRA;

EID: 0032829070     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F     Document Type: Article

References (38)

1. Langston JW, Ballard P, Tetrud J, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
2. Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopamine neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 1983;80:4546-4550
3. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394
4. Chiba K, Trevor AJ, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578
5. +): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984;48:87-92
6. Markey SP, Johannessen JN, Chiueh CC, et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467
7. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984;224:1451-1453
8. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neutons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Proc Natl Acad Sci USA 1985;2173-2177
9. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADP-linked oxidation of brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 1985;36:2503-2508
10. +, Biochem Biophys Res Commun 1986;134:743-748
11. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-346
12. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurology 1985;35:949-956
13. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254
14. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: implications for treatment and the pathophysiology of Parkinson's disease. Can J Neurol Sci 1984;11:160-165
15. Graeber MB, Bise KB, Mehraein P. CR3/43, a marker for activated microglia: application to diagnostic neuropathology. Neuropathol Appl Neurobiol 1994;20:406-408
16. Langston JW, Irwin I, Langston EB, et al. MPTP-induced parkinsonism in humans: a review of the syndrome and observations relating to the phenomenon of tardive toxicity. In: Markey SP, Castagnoli N Jr, Trevor AJ, Kopin IJ, eds. MPTP: a neurotoxin producing a parkinsonian syndrome. New York: Academic Press, 1986:9-21
17. Spencer PS, Kisby GE, Ludolph AC. Slow toxins, biologic markers, and long-latency neurodegenerative disease in the western Pacific region. Neurology 1991;41:62-66
18. Stone R. Guam: deadly disease dying out. Science 1993;261: 424-426
19. Kisby GE, Ross SM. Spencer PS, et al. Cycasin and BMAA: candidate neurotoxins for western Pacific amyotrophic lateral sclerosis/parkinsonism-dementia complex. Neurodegeneration 1992;1:73-82
20. Zhang ZX, Anderson DW, Mantel N, Roman GC. Motor neuron disease on Guam: geographic and familial occurrence, 1956-85. Act Neurol Scand 1996;94:51-59
21. Garruto RM, Gajdusek DC, Chen KM. Amyotrophic lateral sclerosis among Chamorro migrants from Guam. Ann Neurol 1980;8:612-619
22. Perl DP. Amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. In: Esiri MM, Morris JH, eds. The neuropathology of dementia. Cambridge: Cambridge University Press, 1997:184-203
23. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988;38: 1285-1291
24. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221-227
25. Vingerhoers FJG, Snow BJ, Tetrud JW, et al. PET evidence for progression of human MPTP-induced lesions. Ann Neurol 1994;36:765-770
26. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16:439-444
27. Youdim MBH, Ben-Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 1989;126:47-54
28. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992;32:799-803
29. Blum-Degen D, Muller T, Kuhn W, et al. Interleukin-1 and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202:17-20
30. Mogi M, Harada M, Narabayashi H, et al. Interleukin (IL)-1, IL-2, IL-4, IL-6 and transforming growth factor-β levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996;211:13-16
31. Mogi M, Harada M, Kondo T, et al. Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor-1 are elevated in the brain from parkinsonian patients. Neurosci Lett 1994;180:147-150
32. Vawter MP, Dillon-Carter O, Tourtellotte WW, et al. TGF-1 and TGF-2 concentrations are elevated in Parkinson's disease ventricular cerebrospinal fluid. Exp Neurol 1996;142:313-322
33. Boka G, Anglade P, Wallach D, et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172:151-154
34. Mogi M, Harada M, Riederer P, et al. Necrosis factor-1 (TNF-1) increases both in the brain and in the cerebrospinal fluid from Parkinson patients. Neurosci Lett 1994;165:208-210
35. Giulian D, Li J, Li X, et al. The impact of microglia-derived cytokines upon gliosis in the CNS. Dev Neurosci 1994;16: 128-136
36. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease: neuropathologic considerations. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. 10th International Symposium on Parkinson's Disease: From basic research to treatment. Advances in neurology, vol 60. New York: Raven Press, 1993:600-608
37. + binds to neuromelanin. Science 1986;231:987-989
38. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleusmediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44(Suppl 1):S175-S188